Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S0392-0488.16.05520-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials.
Dermatol Ther (Heidelb)
January 2025
Medical Direction Pharmaceutical Care and Medical Dermatology, Pierre Fabre Dermatologie, Les Cauquillous, 81500, Lavaur, France.
Introduction: Topical 5-fluorouracil (5-FU), 5% or 4% cream, is recommended among first-line treatments for actinic keratosis (AK). Local skin reactions (LSRs) are an expected and transient response to treatment with 5-FU but can lead to treatment discontinuation when severe. This analysis aimed to investigate whether the severity of LSRs during the treatment was associated with lesion clearance assessed 4 weeks after completing treatment.
View Article and Find Full Text PDFNeonatal epididymo-orchitis (EO) is a rare condition, particularly when caused by S, a pathogen typically associated with gastroenteritis. We present the case of a 15-day-old male who developed right-sided scrotal swelling and erythema. Scrotal ultrasound confirmed EO without signs of torsion or abscess.
View Article and Find Full Text PDFSpectrum of bacterial pathogens in inflammatory and noninflammatory cutaneous ulcers of American tegumentary leishmaniasis.
Ther Adv Infect Dis
September 2024
Temerty Faculty of Medicine, University of Toronto, ON, Canada.
Background: Cutaneous leishmaniasis (CL) ulcers exhibiting an inflammatory phenotype, characterized by purulent exudate, erythema, pain, and/or lymphatic involvement, are empirically treated with antibiotics.
Objective: The spectrum of bacteria present in localized versus inflammatory phenotypes of CL is elucidated herein.
Methods: Filter paper lesion impressions (FPLIs) from 39 patients with CL (19 inflammatory and 20 noninflammatory ulcers) were evaluated via real-time polymerase chain reaction (qPCR) and end-point PCR targeting: , , , spp.
VEXAS-Syndrome, a newly described autoinflammatory systemic disease with dermatologic manifestations.
J Dtsch Dermatol Ges
December 2023
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
VEXAS syndrome is a recently identified autoinflammatory systemic disease caused by an acquired somatic mutation of the X-linked UBA1 gene, the key enzyme of the first step of ubiquitylation. The acronym VEXAS stands for the characteristics Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic. The disease occurs in advanced adulthood preferentially in men and is characterized by hematological, rheumatological and dermatological symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!